Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

- Patients >=18 years with secondary hyperparathyroidism (iPTH >= 300 pg/mL) - Patients in a chronic hemodialysis or peritoneal dialysis program previously treated with vitamin D metabolites or without previous treatment - Patients in which treatment with paricalcitol injection or oral is clinically indicated according to the criteria of the participating investigator - Patients providing their signed informed consent to participate in the trial

- Patients with severe hyperparathyroidism (iPTH > 3,000 pg/ml) - Patients with hypercalcaemia (calcium >=11.0 mg/dl, adjusted according to Albumin level), hyperphosphataemia (phosphorus >= 6.5 mg/dl) or patients with calcium x phosphorus >= 70 - Known hypersensitivity and/or toxicity to vitamin D metabolites and/or other product ingredients - Patients who have participated in clinical studies within the last month or who are currently enrolled in clinical studies - Patients who cannot tolerate or take phosphorus binders that do not contain Calcium and/or Aluminum - Patients that in the opinion of the investigator, for any reason, are not good candidates for therapy with Synthetic Analogues of Vitamin D